Impact of complement activation on clinical outcomes in multiple sclerosis

Area of Science:

• Immunology
• Neurology
• Biochemistry

Background:

• The complement system plays a role in inflammatory and autoimmune diseases.
• Multiple Sclerosis (MS) is a chronic inflammatory disease of the central nervous system.
• Biomarkers are needed to monitor disease activity and progression in early MS.

Purpose of the Study:

• To investigate the activation profiles of the classical and alternative complement pathways in treatment-naïve patients with early relapse-onset MS.
• To determine if complement activation correlates with disease activity, lesion load, or long-term outcomes in early MS.

Main Methods:

• Measured plasma concentrations of complement activation fragments in 39 early MS patients and 32 controls with non-inflammatory neurological diseases.
• Compared complement profiles between MS patients and controls, and between stable and relapsing MS patients.
• Correlated complement levels with baseline Expanded Disability Status Scale (EDSS), T2 lesion counts, time to second relapse, and 4-year EDSS outcomes.

Main Results:

• Plasma complement fragment concentrations were similar in MS patients and controls.
• Complement activation profiles did not differ between patients with stable disease and those experiencing exacerbations.
• Baseline complement levels showed no significant correlation with EDSS, T2 lesions, time to second relapse, or long-term EDSS outcomes.

Conclusions:

• Current data do not support the use of complement activation products as biomarkers for disease activity in early MS.
• Further research may be needed to explore other potential roles or markers within the complement system in MS.